A Clinical Study of SHP674 in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia


The objectives of the study are to 1) assess the safety and tolerability of a single dose of Pegaspargase in Japanese patients (dose confirmation) in the tolerability assessment period; and 2) to assess the safety, pharmacokinetics and efficacy of Pegaspargase in the treatment of newly diagnosed untreated acute lymphoblastic leukemia in Japanese patients.

Full Title of Study: “A Phase 2 Clinical Study of Pegaspargase in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 3, 2021


  • Biological: Pegaspargase
    • Pegaspargase : powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m2: 2500 IU/m2 every 14 days if BSA <0.6 m2: 82.5 IU/kg every 14 days

Arms, Groups and Cohorts

  • Experimental: Pegaspargase arm

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of patients who have a plasma asparaginase activity of ≥0.1 IU/mL 14 days (336 hours) after the first dose of Pegaspargase
    • Time Frame: 14 days after the first dose of Pegaspargase in Remission Induction phase

Secondary Measures

  • Incidence and nature of treatment-emergent adverse events (TEAEs) and drug-related TEAEs
    • Time Frame: Up to 1 year
  • Plasma Asparaginase Activity with therapeutic threshold of 0.1 IU/mL Asparaginase measured by coupled enzymatic activity assay
    • Time Frame: Prior to, and including 11, 14, and 25 days after Pegaspargase administration
  • Survival rate at 1 year after the start of study treatment
    • Time Frame: 1 year after the start of study treatment
  • Event-free survival rate at 1 year after the start of study treatment
    • Time Frame: 1 year after the start of study treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Age 1 to ≤21 years at the time of informed consent; – Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2; – Newly diagnosed, untreated precursor B-cell ALL – No prior therapy for malignant tumor such as chemotherapy and radiation therapy before signing the informed consent; – Life expectancy of at least 6 months from the date of enrollment; Exclusion Criteria:

  • Mature B-cell ALL ; Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL – Preexisting known coagulopathy ; – History of pancreatitis; – Continuous use of corticosteroids; – Prior treatment or possible prior treatment with an L-asparaginase preparation; – History of sensitivity to polyethylene glycol (PEG) or PEG-based drugs; – Pregnant

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 21 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut de Recherches Internationales Servier
  • Collaborator
    • Kyowa Kirin Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Chitose Ogawa, MD, Principal Investigator, National Cancer Center Hospital, Tokyo JAPAN

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.